ESBL-producing E. coli in uncomplicated UTI - Regional and Austria-wide update and evaluation of treatment options;ESBL-produzierende E. coli als erreger der ambulant erworbenen harnwegsinfektion - Aktuelle resistenzsituation in Österreich und konsequenzen für die therapie

Hygiene + Medizin

Volumn 35, Issue 1-2, 2010, Pages 26-31

  Hell, Markus ^a  

^a Facharzt für Hygiene und Mikrobiologie Infektiologie und Tropenmedizin   (Austria)

Author keywords

ESBL producing E. coli; Resistance situation; Treatment options; Uncomplicated urinary tract infection

Indexed keywords

EID: 79955863082     PISSN: 01723790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rodríguez-Baño J, Navarro MD. Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:104-10. (Pubitemid 350284181)
2. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006 Apr; 57(4):780-3. Epub 2006 Feb. 21.
3. Kola A, Holst M, Chaberny IF, Ziesing S, Suerbaum S, Gastmeier P. Surveillance of extendedspectrum beta-lactamase-producing bacteria and routine use of contact isolation: experience from a three-year period. J Hosp Infect. 2007 May; 66(1):46-51. (Pubitemid 46657123)
4. Arpin C, Quentin C, Grobost F, Cambau E, Robert J, Dubois V, Coulange L, Andr C; Scientific Committee of ONERBA. Nationwide survey of extendedspectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting J Antimicrob Chemother. 2009 Jun; 63(6):1205-14. Epub 2009 Mar. 28.
5. Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, Baquero F, Cantón R. Antibiotic coresistance in extended-spectrumbeta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother. 2006 Aug; 50(8):2695-9. (Pubitemid 44198689)
6. Hell M. AURES 2008 - Resistenzbericht für ausgewählte nicht invasive Erreger, S.85-93. URL: http://www.bmg.gv. at/cms/site/standard.html? channel=CH0742&doc=CMS1203598507001
7. Hahn H, Falke D, Kaufmann SHE, Ullman U. Medizinische Mikrobiologie und Infektiologie (5. Aufl.). Springer Verlag Berlin, 2004.
8. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:79-83.
9. Crane G. Fosfomycin trometamol - Product monpgraph. Excerpta Medica - An Elsevier Science Company, Torrex Pharma Vienna Austria. 2002. URL: http://www.monuril.at/Monuril-Monograph.pdf (07.12.07)
10. Alexander M, Estler CJ, Legler F. Antibiotika und Chemotherapeutika: bakteriologische Grundlagen, Pharmakologie und therapeutischer Einsatz antibakteriell wirksamer Arzneistoffe. Wiss. Verl.-Ges. Stuttgart, 1990.
11. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO SENS Project. J Antimicrob Chemother. 2003 Jan; 51(1):69-76. (Pubitemid 36163829)
12. Leo Pharma Selexid Product Monographie. Leo Pharma Ges.m.b. H., 1060 Wien, URL: 2005 http://www.akh-consilium.at/produkteseiten/infos/leo-selexid- produktmonografie.pdf (07.12.07)
13. Graninger W. Pivmecillinam - therapy of choice for lower urinary tract infection. Internation Journal of Antimicrobial Agents. 2003, 22:78.
14. CLSI, Wayne, PA. Performance Standards for Antimicrobial Susceptibility Testing. Approved standard M100-S17 2007, 27-1.
15. CLSI, Wayne, PA. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data. Approved Guideline. M39-A2, 25-28.
16. CMI Cornaglia G, Hryniewicz W, Jarlier V, Kahlmeter G, Mittermayer H, Stratchounski L, Baquero F; ESCMID Study Group for Antimicrobial Resistance Surveillance: European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect. 2004 Apr; 10(4):349-83. (Pubitemid 38519367)
17. Nicolle LE, Mulvey MR. Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis. 2007;39(8):748-9. (Pubitemid 47180483)
18. de Cueto M, Hernández JR, López-Cerero L, Morillo C, Pascual A. Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm Infecc Microbiol Clin. 2006 Dec; 24(10):613-6. (Pubitemid 46141730)
19. Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell AJ, Moran KA. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob. 2007 Jun. 6; 6:6.
20. Tamayo J, Orden B, Cacho J, Cuadros J, Gomez-Garces JL, Alos JI. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid. Rev Esp Quimioter. 2007 Sep; 20(3):334-8. (Pubitemid 350240493)
21. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother. 2004 Jun; 53 Suppl 2: ii11-21.
22. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamaseproducing Enterobacteriaceae. Antimicrob Agents Chemother. 2005 May; 49(5):2137-9. (Pubitemid 40631641)
23. Babypadmini S, Appalaraju B. Extended spectrum-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae - Prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol. 2004 Jul-Sep; 22(3):172-4. (Pubitemid 39206740)